Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02104219 · ClinicalTrials.gov registry record
Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)
A clinical trial, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- 32
- Enrollment target
NCT02104219: Completed study, sponsored by Alexion Pharmaceuticals.
NCT02104219 is a clinical trial that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02104219 has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the natural history of HPP in patients with Juvenile-onset HPP.
Primary Outcome
The RGI-C scale is a 7-point ordinal scale that is used to evaluate musculoskeletal characteristics of HPP (eg, metaphyseal fraying, demineralization of distal metaphyses). The scores range from -3 (severe worsening) to +3 (complete or near-complete healing).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-09 |
What the finished NCT02104219 record still lists
NCT02104219 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02104219 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02104219 about?
NCT02104219 is a clinical study titled "Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)". The purpose of this study is to characterize the natural history of HPP in patients with Juvenile-onset HPP.
What is the current status of trial NCT02104219?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2014-03. Estimated completion is 2014-09.
Who is sponsoring clinical trial NCT02104219?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia